Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
120.40 ^USD	-2.28%		-0.68%	+30.35%

12-12	Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	CI
12-12	Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	DJ

Analyst Reco.

Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating	12-12	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating	12-10	MT
HSBC Adjusts Price Target on Gilead Sciences to $133 From $110, Maintains Hold Rating	12-10	MT
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	12-10
Mizuho Adjusts Price Target on Gilead Sciences to $140 From $131, Maintains Outperform Rating	11-21	MT
Needham Adjusts Gilead Sciences Price Target to $140 From $133, Maintains Buy Rating	11-13	MT
Daiwa Securities Adjusts Gilead Sciences Price Target to $129 From $128, Maintains Outperform Rating	11-13	MT
Scotiabank Initiates Gilead Sciences at Sector Outperform With $140 Price Target	11-13	MT
Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $153 From $143	11-10	MT
Gilead provides update on phase 3 ASCENT-07 study	11-07	RE
Argus Research Adjusts Gilead Sciences Price Target to $135 From $130, Maintains Buy Rating	11-04	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating	10-31	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating	10-31	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $145 From $140, Maintains Overweight Rating	10-31	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating	10-31	MT
RBC Capital Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Sector Perform Rating	10-31	MT
Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating	10-23	MT
TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating	10-23	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Outperform Rating	10-20	MT
Goldman Sachs Raises Gilead Sciences Price Target to $108 From $105, Neutral Rating Maintained	10-17	MT
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025	10-13	CI
Assembly Biosciences, Inc. Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections Europe	10-10	CI
Cantor Fitzgerald Adjusts PT on Gilead Sciences to $135 From $129, Maintains Overweight Rating	10-09	MT
Citigroup Adjusts Price Target on Gilead Sciences to $135 From $125, Maintains Buy Rating	10-08	MT
RBC Lifts Price Target on Gilead Sciences to $100 From $98, Keeps Sector Perform Rating	10-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 09:09 am